



NIVIRON

incorporated

NIVIRON

Is a preclinical stage company translating technologies for cancer treatment to bedside

Founding Niviron INC

July 30, 2021
registered State of Delaware, USA



Company mission

Increasing human longevity through the development of new technologies for the treatment of diseases



Our focus

Cancer therapy with oncolytic viruses




The main task

Build an infrastructure that allows bringing technologies for the treatment of diseases to the market



The motive of company creation

There are many unresolved problems and tasks in medicine, as well as there is a clear confidence we want to and can solve them



OUR TEAM

Scientific Advisory Council



**Alexis
Kafando**

PhD (Virology)

Principal Investigator



**Bolni Marius
Nagalo**

PhD (Virology)

Consultant



**Darrick
Carter**

PhD

Consultant



**Henry
Fechner**

DVM

Consultant

Technology Inventor

OUR TEAM

Co-founders



**Sheremet
Vitaly**

Company investor



**Shapovalov
Nikita**

CEO

Office



**Lokotko
Elizaveta**

HR/Transfer Technology



**Guzei
Oxana**

Investor Relations

PIPELINE

TECHNOLOGY	TECHNICAL TASK	DISCOVERY	PRE-CLINICAL		IND	MAJOR TARGET
			GMP	GLP		
Oncolytic Coxsackievirus						
Use of Engineered Jurona Virus*						
Herpes Virus (IL15 expressing)*						
Herpes Virus (IL12 expressing)*						
Technology of delivery of oncolytic viruses by immune cells						

*We reached a verbal agreement with the university. The process of signing the agreement is underway.

BUSINESS MODEL

Funding rounds

1 Preclinical trials
Obtaining **IND**

Sources:

- Angel investors
- Early stage venture funds
- Accelerators

2 **Phase I**
Clinical trials

Sources:

- Venture fund
- Corporate venture funds
- Agreements on joint research with big pharma

Selling a technology or company

3 **Phase II**
Clinical trials

Sources:

- Venture fund
- Corporate venture funds
- Agreements on joint research with big pharma
- IPO

Selling a technology or a block of shares

4 **Phase III**
Clinical trials


Sources:

- Venture fund
- Corporate venture funds
- Agreements on joint research with big pharma
- IPO
- Advance payment for the transfer of rights to a technology or company

Selling a technology or a block of shares


5 **FDA**
Approval

Reinvesting
Profits in the development of other technologies



MARKET VOLUME

The main statistical data of the disease



1,5 M 151 K 52 K
Colorectal cancer



89 K 62 K 49 K
Pancreatic cancer



1,3 M 99 K 7 K
Melanoma



100 K 41 K 30 K
Liver cancer



176 K 25 K 18 K
Brain cancer

ROUND BUDGET

We need to achieve our goals

Required amount: **5 000 000 \$**

Period: **2 years**

We offer to invest not only in the technology we have described, but also we want you to invest in our team, business model and our future. You will find our company as a long-term partner that will create assets for its investors in the course of its existence.

Tasks for this period

- Conduct preclinical trials
- Obtain IND
- Form a team to conduct clinical trials
- Find financing for the next stage

THANK YOU

for your attention, we will be glad to receive feedback, including about our shortcomings we will correct in the near future, if it does not concern our long-term strategy.

2022



101 Arch Street 8th Floor Boston Massachusetts
02110 United States of America

CEO: shapovalov@niviron.net
Investor relations: oksana@niviron.net

niviron.net